Treatment Access

Treatment-Access Pathways

Finding the right next step is not always limited to published studies or clinical trials alone. In some cases, patients and families also want to understand whether there are legitimate access pathways that may be worth discussing with their medical team, particularly when standard options are limited, time is critical, or trial participation is not possible. In the United States, official pathways include expanded access and, in some cases, Right to Try. In Europe, compassionate use programmes may exist, but they are coordinated at Member State level and can vary by country.

At Next Option Research, we help clients and families understand these pathways in a clearer and more structured way. Our role is to research what may exist, explain how these routes generally work, and identify what may be worth raising with the appropriate medical professionals. We do not provide medical advice, diagnosis, or treatment, and we do not guarantee access, eligibility, or outcomes. Any pathway we identify must be reviewed directly with the relevant medical team or institution.

This area can be difficult to navigate because access pathways often depend on multiple factors at once: diagnosis, severity of illness, whether standard treatments remain, whether a clinical trial is available, whether a company is willing to provide an investigational product, and which national rules apply. The FDA says expanded access is a potential route for serious or immediately life-threatening conditions when no comparable or satisfactory alternative exists and trial enrollment is not possible. The NCI similarly notes that expanded access requires a doctor’s involvement and that a company may decline to provide the drug. For Right to Try, NCI notes that the process also depends on a doctor’s help and whether the company is willing to provide the investigational drug.

In Europe, compassionate use works differently. The EMA explains that it can provide recommendations, but those recommendations do not themselves create the legal framework; Member States coordinate and implement their own programmes and procedures. The EMA also notes that patients should generally be considered for clinical trials before compassionate use is offered.

Our process begins with a free case assessment so we can understand the situation and decide whether deeper research is likely to add value. If we believe further support is appropriate, we may research relevant treatment-access pathways, practical considerations, and possible next steps for discussion with the treating medical team. Our role is to help bring clarity to a complex process, not to replace a doctor or remain involved in treatment decisions once the appropriate connections have been made.

Useful links below:

FDA Right to Try
Explains the U.S. Right to Try pathway for certain patients with life-threatening conditions who have tried approved options and cannot join a clinical trial.

NCI Access to Experimental Cancer Drugs
 A cancer-specific overview of the main routes to investigational drugs, including clinical trials, expanded access, and Right to Try.

EMA Compassionate Use
Explains the European compassionate use framework and how access is coordinated through EU member states rather than one single EU-wide approval route.